Lung Cancer
Brigatinib-3001- A Phase 3 Randomized Open-label Study of Brigatinib (ALUNBRIG�)Versus Alectinib (ALECENSA�) in Advanced Anaplastic Lymphoma Kinase-Positive Non�Small-Cell Lung Cancer Patients Who Have Progressed on Crizotinib (XALKORI�)
- Details
ClinicalTrials.gov ID:
NCT03596866
Diagnosis Type:
NA
USOR Number:
- Address
310 Smith Ave N
Suite 100
Saint Paul, MN 55102
P: (651) 251-5500